Scott Maxson Email Address

Senior Director, Process Development and Denver Site Director

Atara Biotherapeutics, Inc. is a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, with an initial focus on immunotherapy and oncology. Atara Bio's programs include T-cell product candidates and molecularly targeted product candidates. The T-cell product candidates include EBV-CTL, CMV-CTL, and Wilms Tumor 1 targeted Cytotoxic T-cells (WT1-CTL) and harness the power of the immune system to recognize and attack cancer cells and cells infected with certain viruses. The molecularly targeted product candidates include STM 434. These product candidates target activin and myostatin, members of the TGF-beta family of proteins, and have demonstrated the potential to have therapeutic benefit in a number of clinical indications.

I am a highly self-motivated and adaptive scientist with extensive laboratory and leadership skills. I have a Ph.D. in Bioengineering and several years of industry experience. My work has provided me with extensive experience with stem isolation, culture, differentiation and cryopreservation. In have been the lead scientist in the area of Cell Therapy Process Development on numerous different projects. In addition I am very knowledgeable in the areas of tissue engineering and regenerative medicine. During my time in industry, I have gained experience developing comprehensive long term and short term research plans for various different projects. Additionally, I am experienced with all phases of process development from conception to launch.